About Mai Hoang, MD

Dr. Hoang is an anatomic pathologist specializing in dermatopathology. She is currently the director of Dermatopathology at Massachusetts General Hospital. She has served as the medical director of the Pathology immunohistochemistry laboratory at Mass General Hospital from 2012-2019 and the course director of the annual Harvard Combined Dermatopathology Update course from 2008-2017. She serves on the editorial boards of the Journal of the American Academy of Dermatology and the American Journal of Dermatopathology. She has published over 150 peer-reviewed articles, and has authored and co-edited five books: Melanocytic Lesions: a Case Based Approach, Vulvar Pathology, Cutaneous Hematopathology, Immunohistochemistry in Diagnostic Dermatopathology and Hospital-Based Dermatopathology: a Guide to Diagnosis.

Departments, Centers, & Programs:

Clinical Interests:




Mass General Pathology
55 Fruit St.
Boston, MA 02114
Phone: 617-643-0800

Medical Education

  • MD, UT Southwestern Medical School
  • Residency, UT Southwestern Medical Center
  • Fellowship, Duke University Medical Center
  • Fellowship, University of Texas - MD Anderson Cancer Center

American Board Certifications

  • Anatomic Pathology and Clinical Pathology, American Board of Pathology
  • Dermatopathology, American Board of Pathology

Accepted Insurance Plans

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.


Dr. Hoang's research interests focus on the role of immunohistochemistry as ancillary diagnostic tools in pathology and as predictive/prognostic markers in rare cutaneous tumors. Several of her studies have highlighted the role of immunostains in distinguishing benign versus malignant adnexal neoplasms, porocarcinoma versus squamous cell carcinoma, and primary adnexal carcinomas versus cutaneous metastases. Validation studies have confirmed the role of BRAFV600E, BAP1, and ROS1 immunostains as sensitive, specific, and cost-effective screening tests in detecting underlying molecular abnormalities. Recent works from an international collaborative effort with investigators from 10 clinical centers in the U.S., Spain, Poland, and Taiwan, have highlighted the prognostic role of gene mutation (NRAS, KIT, BRAF, SF3B1), some biomarkers and immune infiltrates in mucosal melanomas, desmoplastic melanomas and Merkel cell carcinomas. For more information about research concepts, co-authors, and to see a timeline, visit  Dr. Hoang's profile at the Harvard Clinical and Translational Science Center.


    1. Donizy P, Wu C-L, Mull J, Fujimoto M, Chlopik A, Peng Y, Shalin SC, Selim MA, Puig S, Fernandez-Figueras MT, Shea CR, Biernat W, Rys J, Marszalek A, Hoang MP. Up-regulation of PARP-1 expression significantly correlated with poor survival in mucosal melanomas. Cells. 2020;9(5):1135; https://doi.org/10.3390/cells9051135.
    2. Hoang MP, Donizy P, Wu C-L, Kopzynski J, Pieniazek M, Miller DM, Rys J. Tdt expression is a marker of better survival in Merkel cell carcinoma; and expression of B-cell markers is associated with Merkel cell polyomavirus. Am J Clin Pathol. 2020;154(1);38-47.
    3. Wroblewska JP, Mull J, Wu C-L, Fujimoto M, Ogawa T, Marszalek A, Hoang MP. SF3B1, NRAS, KIT and BRAF mutation; and CD117 and cMYC expression in sinonasal melanomas: an analysis with newly found molecular alterations and some population based molecular differences. Am J Surg Pathol. 2019;43:168-177.
    4. Dias-Santagata D, Selim MA, Su Y, Peng Y, Vollmer R, Chlopik A, Tell-Marti G, Paral K, Shalin SC, Shea CR, Puig S, Fernandez-Figueras M, Biernat W, Rys J, Marszalek A, Hoang MP. KIT mutation and CD117 overexpression are markers of better progression-free survival in vulvar melanomas. Br J Dermatol. 2017;177:1376-1384.
    5. Kraft SR, Fernandez-Figueras MT, Richarz NA, Flaherty KT, Hoang MP. PDL1 expression in desmoplastic melanoma is associated with tumor aggressiveness and progression. J Am Acad Dermatol. 2017;77:534-542.

Reviews: Comments and Ratings